Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Abstract
Neurodegenerative diseases such as Alzheimer’s disease have proven resistant to new treatments. The complexity of neurodegenerative disease mechanisms can be highlighted by accumulating evidence for a role for a growth factor, progranulin (PGRN). PGRN is a glycoprotein encoded by the GRN/Grn gene with multiple cellular functions, including neurotrophic, anti-inflammatory and lysosome regulatory properties. Mutations in the GRN gene can lead to frontotemporal lobar degeneration (FTLD), a cause of dementia, and neuronal ceroid lipofuscinosis (NCL), a lysosomal storage disease. Both diseases are associated with loss of PGRN function resulting, amongst other features, in enhanced microglial neuroinflammation and lysosomal dysfunction. PGRN has also been implicated in Alzheimer’s disease (AD). Unlike FTLD, increased expression of PGRN occurs in brains of human AD cases and AD model mice, particularly in activated microglia. How microglial PGRN might be involved in AD and other neurodegenerative diseases will be discussed. A unifying feature of PGRN in diseases might be its modulation of lysosomal function in neurons and microglia. Many experimental models have focused on consequences of PGRN gene deletion: however, possible outcomes of increasing PGRN on microglial inflammation and neurodegeneration will be discussed. We will also suggest directions for future studies on PGRN and microglia in relation to neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lastly, both GRN and TMEM106B have already been associated with neuropathological features of AD46–48.”
From New insights into the genetic etiology of Alzheimer’s disease and related dementias (2022) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493 · cited 2×
“Recent studies employing single-cell microglia RNA sequencing showed upregulation of Grn mRNA expression in microglia, derived from AD model mice, that had been characterized as having the “disease-associated microglia” (DAM) phenotype, a recently defined late-activation phenotype associated with microglia that restri…”
BackgroundThe M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058 · cited 1×
“Initial papers observed features of PGRN immunoreactivity in microglia around senile plaques in AD cases when comparison was being made with neuropathological features of FTLD due to GRN mutations [13,127].”
ResultElmore, M. R. P., Najafi, A. R., Koike, M. A., Dagher, N. N., Spangenberg, E. E., Rice, R. A., Kitazawa, M., Matusow, B., Nguyen, H., West, B. L., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.040 · Cited by 1,968
Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration
Deczkowska, A., Keren-Shaul, H., Weiner, A., Colonna, M., Schwartz, M., & Amit, I. (2018) · Cell · doi:10.1016/j.cell.2018.05.003 · Cited by 1,474 · cited 1×
“Recent studies employing single-cell microglia RNA sequencing showed upregulation of Grn mRNA expression in microglia, derived from AD model mice, that had been characterized as having the “disease-associated microglia” (DAM) phenotype, a recently defined late-activation phenotype associated with microglia that restri…”
BackgroundTang, W., Lu, Y., Tian, Q.-Y., Zhang, Y., Guo, F.-J., Liu, G.-Y., Syed, N. M., Lai, Y., Lin, E. A., Kong, L., et al. (2011) · Science · doi:10.1126/science.1199214 · Cited by 761 · cited 2×
“It had been speculated that if PGRN could function by blocking TNF-α activation, it would provide a rationale for the use of PGRN in diseases involving excess TNF-α including RA [95].”
BackgroundLui, H., Zhang, J., Makinson, S. R., Cahill, M. K., Kelley, K. W., Huang, H.-Y., Shang, Y., Oldham, M. C., Martens, L. H., Gao, F., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.001 · Cited by 729 · cited 7×
“Increased numbers of activated microglia and C1qa immunoreactivity were also observed in human FTLD GRN mutation carriers but not in AD cases [10].”
BackgroundResultInfluentialSpangenberg, E. E., Lee, R. J., Najafi, A. R., Rice, R. A., Elmore, M. R. P., Blurton-Jones, M., West, B. L., & Green, K. N. (2016) · Brain · doi:10.1093/brain/aww016 · Cited by 695
Conversion of Proepithelin to Epithelins
Zhu, J., Nathan, C., Jin, W., Sim, D., Ashcroft, G. S., Wahl, S. M., Lacomis, L., Erdjument-Bromage, H., Tempst, P., Wright, C. D., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)01141-8 · Cited by 633 · cited 1×
“PGRN cleavage is prevented by secretory leukocyte protease inhibitor (SLPI), which binds directly to PGRN linker sequences [49].”
BackgroundMutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration
Gass, J., Cannon, A., Mackenzie, I. R., Boeve, B., Baker, M., Adamson, J., Crook, R., Melquist, S., Kuntz, K., Petersen, R., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl241 · Cited by 580
Sortilin-Mediated Endocytosis Determines Levels of the Frontotemporal Dementia Protein, Progranulin
Hu, F., Padukkavidana, T., Vægter, C. B., Brady, O. A., Zheng, Y., Mackenzie, I. R., Feldman, H. H., Nykjaer, A., & Strittmatter, S. M. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.034 · Cited by 536 · cited 3×
“One question is whether microglial expressed PGRN, which can be detected intracellularly by immunohistochemistry (see Figure 2), mainly in lysosomes, has anti-inflammatory properties or whether PGRN needs to be secreted and/or to bind membrane receptors such as TLR-9 [103], sortilin [44], receptor tyrosine kinase rece…”
BackgroundProgranulin is a mediator of the wound response
He, Z., Ong, C. H. P., Halper, J., & Bateman, A. (2003) · Nature Medicine · doi:10.1038/nm816 · Cited by 490 · cited 1×
“PGRN (also known as epithelin precursor, acrogranin, PC-derived growth factor, GEP, GP88, PEPI, and CLN11) and its granulin cleavage products were first identified in 1992 as growth factors involved in wound healing, vessel growth and cancer [11,12].”
BackgroundStrikingly Different Clinicopathological Phenotypes Determined by Progranulin-Mutation Dosage
Smith, K. R., Damiano, J., Franceschetti, S., Carpenter, S., Canafoglia, L., Morbin, M., Rossi, G., Pareyson, D., Mole, S. E., Staropoli, J. F., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.04.021 · Cited by 489 · cited 7×
“FTLD can be caused by mutations in a single allele of GRN, while NCL is caused by mutations in both alleles.”
BackgroundInfluentialMacrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis
Nielsen, S. R., Quaranta, V., Linford, A., Emeagi, P., Rainer, C., Santos, A., Ireland, L., Sakai, T., Sakai, K., Kim, Y.-S., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3340 · Cited by 441
Gowrishankar, S., Yuan, P., Wu, Y., Schrag, M., Paradise, S., Grutzendler, J., De Camilli, P., & Ferguson, S. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510329112 · Cited by 406
Cellular Localization of Gene Expression for Progranulin
Daniel, R., He, Z., Carmichael, K. P., Halper, J., & Bateman, A. (2000) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540004800713 · Cited by 346 · cited 1×
“Studies of Grn mRNA expression by in situ hybridization in mice showed expression only in classes of neurons (cerebellar Purkinje neurons, hippocampus pyramidal neurons and certain cortical neurons) [54].”
BackgroundProgranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury
Martens, L. H., Zhang, J., Barmada, S. J., Zhou, P., Kamiya, S., Sun, B., Min, S.-W., Gan, L., Finkbeiner, S., Huang, E. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63113 · Cited by 315 · cited 2×
“Using the dopaminergic toxin MPTP to create a model of Parkinson’s disease (PD), increased neuronal cell loss and numbers of activated microglia were seen in the substantia nigra pars compacta (SNpc) of toxin-treated mice with Grn gene deletion compared to toxin-treated control mice [65].”
The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene
Mackenzie, I. R. A., Baker, M., Pickering-Brown, S., Hsiung, G.-Y. R., Lindholm, C., Dwosh, E., Gass, J., Cannon, A., Rademakers, R., Hutton, M., et al. (2006) · Brain · doi:10.1093/brain/awl271 · Cited by 297 · cited 1×
“Evidence of lysosomal dysfunction due to compromised protein degradation was an early observation in brains from cases with FTLD due to GRN mutations and linked PGRN to lysosomal function [140,141].”
BackgroundAhmed, Z., Sheng, H., Xu, Y.-F., Lin, W.-L., Innes, A. E., Gass, J., Yu, X., Hou, H., Chiba, S., Yamanouchi, K., et al. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090915 · Cited by 294 · cited 3×
“At 12 and 23 months, these gene deletion mice showed significantly increased numbers of activated microglia, reactive astrocytes, neuronal vacuolation, and neuronal loss, as well as ubiquitin positive cytoplasmic inclusions [110].”
BackgroundInfluentialLuo, J., Elwood, F., Britschgi, M., Villeda, S., Zhang, H., Ding, Z., Zhu, L., Alabsi, H., Getachew, R., Narasimhan, R., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20120412 · Cited by 262
Progranulin, lysosomal regulation and neurodegenerative disease
Kao, A. W., McKay, A., Singh, P. P., Brunet, A., & Huang, E. J. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.36 · Cited by 258
TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers
Finch, N., Carrasquillo, M. M., Baker, M., Rutherford, N. J., Coppola, G., DeJesus-Hernandez, M., Crook, R., Hunter, T., Ghidoni, R., Benussi, L., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31820a0e3b · Cited by 243
Progranulin protects against amyloid β deposition and toxicity in Alzheimer's disease mouse models
Minami, S. S., Min, S.-W., Krabbe, G., Wang, C., Zhou, Y., Asgarov, R., Li, Y., Martens, L. H., Elia, L. P., Ward, M. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3672 · Cited by 237 · cited 9×
“1 with AD models, which indicated the therapeutic potential of PGRN therapy for AD [24], the following two papers derive from the biotechnology company “NeuroDyn” that has made PGRN therapeutics a central therapeutic development program.”
BackgroundMethodInfluentialThe lysosomal function of progranulin, a guardian against neurodegeneration
Paushter, D. H., Du, H., Feng, T., & Hu, F. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1861-8 · Cited by 230
Cenik, B., Sephton, C. F., Kutluk Cenik, B., Herz, J., & Yu, G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.399170 · Cited by 229 · cited 1×
“We will mainly be discussing the full-length protein (PGRN), which has the lysosomal and anti-inflammatory properties; however, under certain conditions PGRN can be cleaved by different proteases to produce granulin fragments [41].”
BackgroundProgranulin in frontotemporal lobar degeneration and neuroinflammation
Ahmed, Z., Mackenzie, I. R., Hutton, M. L., & Dickson, D. W. (2007) · Journal of Neuroinflammation · doi:10.1186/1742-2094-4-7 · Cited by 224
Moisse, K., Volkening, K., Leystra-Lantz, C., Welch, I., Hill, T., & Strong, M. J. (2009) · Brain Research · doi:10.1016/j.brainres.2008.10.021 · Cited by 210 · cited 2×
“Using a sciatic axotomy model of nerve injury, neuronal PGRN was decreased and microglial PGRN increased at sites of nerve damage [107].”
BackgroundGranulins, a novel class of peptide from leukocytes
Bateman, A., Belcourt, D., Bennett, H., Lazure, C., & Solomon, S. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80908-8 · Cited by 206 · cited 1×
“PGRN (also known as epithelin precursor, acrogranin, PC-derived growth factor, GEP, GP88, PEPI, and CLN11) and its granulin cleavage products were first identified in 1992 as growth factors involved in wound healing, vessel growth and cancer [11,12].”
BackgroundProsaposin facilitates sortilin-independent lysosomal trafficking of progranulin
Zhou, X., Sun, L., Bastos de Oliveira, F., Qi, X., Brown, W. J., Smolka, M. B., Sun, Y., & Hu, F. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201502029 · Cited by 203 · cited 1×
“PSAP and PGRN have physical interactions through GRN linker sequences and facilitate trafficking of each other to lysosomes through a sortilin-independent pathway [136,137].”
BackgroundMiguel-Álvarez, M., Santos-Lozano, A., Sanchis-Gomar, F., Fiuza-Luces, C., Pareja-Galeano, H., Garatachea, N., & Lucia, A. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0239-z · Cited by 198 · cited 1×
“Neuroinflammation has long been considered a pathological driver of AD pathology, though anti-inflammatory therapies also have not been effective in halting cognitive decline [6].”
BackgroundGötzl, J. K., Mori, K., Damme, M., Fellerer, K., Tahirovic, S., Kleinberger, G., Janssens, J., van der Zee, J., Lang, C. M., Kremmer, E., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1262-6 · Cited by 197 · cited 3×
“These observations were supported by immunohistochemical staining of affected tissue sections [139].”
BackgroundIndividuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis
Ward, M. E., Chen, R., Huang, H.-Y., Ludwig, C., Telpoukhovskaia, M., Taubes, A., Boudin, H., Minami, S. S., Reichert, M., Albrecht, P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah5642 · Cited by 193 · cited 1×
“Accumulations of lipofuscin, a consequence of lysosomal defects, can be seen in many neurons in tissue sections from most aged human brains with increased amounts of lipofuscin and other markers of lysosomal dysfunction being a feature of brains of FTLD cases with GRN mutations [139,144].”
BackgroundAlteration of behavioural phenotype in mice by targeted disruption of the progranulin gene
Kayasuga, Y., Chiba, S., Suzuki, M., Kikusui, T., Matsuwaki, T., Yamanouchi, K., Kotaki, H., Horai, R., Iwakura, Y., & Nishihara, M. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.07.020 · Cited by 189 · cited 1×
“The first mouse model of FTLD with deletion of both Grn genes showed elevated levels of anxiety and reduced mRNA for the serotonergic receptor 5HT-1A [109].”
BackgroundProminent phenotypic variability associated with mutations in Progranulin
Kelley, B. J., Haidar, W., Boeve, B. F., Baker, M., Graff-Radford, N. R., Krefft, T., Frank, A. R., Jack, C. R., Shiung, M., Knopman, D. S., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.08.022 · Cited by 181 · cited 2×
“A series of cases from different families with GRN mutations were shown to present various clinical phenotypes; however, all that were examined pathologically had frontotemporal degeneration with accumulations of ubiquitinated TAR DNA-binding protein 43 (TDP-43) positive nuclear and cytoplasmic inclusions [20].”
BackgroundYin, F., Dumont, M., Banerjee, R., Ma, Y., Li, H., Lin, M. T., Beal, M. F., Nathan, C., Thomas, B., & Ding, A. (2010) · The FASEB Journal · doi:10.1096/fj.10-161471 · Cited by 180 · cited 1×
“Increased microgliosis has been a consistently observed feature in different Grn deletion mice models [111,112], which established that PGRN deficiency can lead directly or indirectly to increased microglial activation.”
BackgroundProgranulin regulates lysosomal function and biogenesis through acidification of lysosomes
Tanaka, Y., Suzuki, G., Matsuwaki, T., Hosokawa, M., Serrano, G., Beach, T. G., Yamanouchi, K., Hasegawa, M., & Nishihara, M. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx011 · Cited by 180 · cited 4×
“This study also identified through cellular fractionation studies that PGRN was predominantly membrane-associated [148].”
BackgroundResultInfluentialImmune system responses in Parkinson's disease: Early and dynamic
Tansey, M. G., & Romero‐Ramos, M. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14290 · Cited by 178 · cited 1×
“As PD is a neurodegenerative disease also with a significant microglial component in affected brain areas [158,159], such studies of PGRN in human tissues with deposits of aggregated/abnormal α-synuclein could also be productive.”
BackgroundGranulin Is a Soluble Cofactor for Toll-like Receptor 9 Signaling
Park, B., Buti, L., Lee, S., Matsuwaki, T., Spooner, E., Brinkmann, M. M., Nishihara, M., & Ploegh, H. L. (2011) · Immunity · doi:10.1016/j.immuni.2011.01.018 · Cited by 176 · cited 6×
“Of particular interest in relation to inflammation are the following molecules that can interact with PGRN; Toll-like receptor (TLR)-9 [103], sortilin [44,104], receptor tyrosine kinase receptor EphA2 [105] and prosaposin [106].”
BackgroundInfluentialSynaptic dysfunction in progranulin-deficient mice
Petkau, T. L., Neal, S. J., Milnerwood, A., Mew, A., Hill, A. M., Orban, P., Gregg, J., Lu, G., Feldman, H. H., Mackenzie, I. R. A., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.016 · Cited by 173 · cited 1×
“Increased microgliosis has been a consistently observed feature in different Grn deletion mice models [111,112], which established that PGRN deficiency can lead directly or indirectly to increased microglial activation.”
BackgroundProgranulin gene expression regulates epithelial cell growth and promotes tumor growth in vivo.
He, Z., & Bateman, A. (1999) · PubMed · Cited by 171
Klein, Z. A., Takahashi, H., Ma, M., Stagi, M., Zhou, M., Lam, T. T., & Strittmatter, S. M. (2017) · Neuron · doi:10.1016/j.neuron.2017.06.026 · Cited by 165
Tanaka, Y., Matsuwaki, T., Yamanouchi, K., & Nishihara, M. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.06.049 · Cited by 163 · cited 4×
“how microglial PGRN regulated inflammatory activation through reducing excessive lysosomal activation [37].”
BackgroundInfluentialTanaka, Y., CHAMBERS, J. K., Matsuwaki, T., Yamanouchi, K., & Nishihara, M. (2014) · Acta Neuropathologica Communications · doi:10.1186/preaccept-4589926441299369 · Cited by 156 · cited 6×
“FTLD can be caused by mutations in a single allele of GRN, while NCL is caused by mutations in both alleles.”
BackgroundInfluentialArrant, A. E., Onyilo, V. C., Unger, D. E., & Roberson, E. D. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.3081-17.2018 · Cited by 156 · cited 2×
“A recent study used an adeno-associated virus (AAV) Grn expression vector to express PGRN specifically in neurons of Grn deletion mice [147].”
BackgroundMethodProgranulin expression in the developing and adult murine brain
Petkau, T. L., Neal, S. J., Orban, P. C., MacDonald, J. L., Hill, A. M., Lu, G., Feldman, H. H., Mackenzie, I. R. A., & Leavitt, B. R. (2010) · Journal of Comparative Neurology · doi:10.1002/cne.22430 · Cited by 152 · cited 4×
“There was no evidence of PGRN expression by astrocytes [62].”
BackgroundInfluentialAstrocytes, Microglia, and Parkinson’s Disease
Joe, E.-H., Choi, D.-J., An, J., Eun, J.-H., Jou, I., & Park, S. (2018) · Experimental Neurobiology · doi:10.5607/en.2018.27.2.77 · Cited by 144 · cited 1×
“As PD is a neurodegenerative disease also with a significant microglial component in affected brain areas [158,159], such studies of PGRN in human tissues with deposits of aggregated/abnormal α-synuclein could also be productive.”
BackgroundThe neuropathology and clinical phenotype of FTD with progranulin mutations
Mackenzie, I. R. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0223-8 · Cited by 141 · cited 1×
“Evidence of lysosomal dysfunction due to compromised protein degradation was an early observation in brains from cases with FTLD due to GRN mutations and linked PGRN to lysosomal function [140,141].”
BackgroundUddin, M. S., Mamun, A. A., Labu, Z. K., Hidalgo‐Lanussa, O., Barreto, G. E., & Ashraf, G. M. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27588 · Cited by 141 · cited 1×
“With aging and AD, there is significant evidence of lysosomal/autophagic defects in brain [143].”
BackgroundBaba, T., Hoff, H. B., Nemoto, H., Lee, H., Orth, J., Arai, Y., & Gerton, G. L. (1993) · Molecular Reproduction and Development · doi:10.1002/mrd.1080340302 · Cited by 139 · cited 1×
“The human GRN gene codes for a 593 amino acid glycoprotein (PGRN) of 75–80 kDa [39] consisting of highly-conserved 12-cysteine-rich granulin motifs that are tandemly repeated seven and half times [40].”
BackgroundProgranulin: a new avenue towards the understanding and treatment of neurodegenerative disease
Chitramuthu, B. P., Bennett, H. P. J., & Bateman, A. (2017) · Brain · doi:10.1093/brain/awx198 · Cited by 138
Suh, H.-S., Choi, N., Tarassishin, L., & Lee, S. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035115 · Cited by 137 · cited 5×
“By comparison, PGRN expression by astrocytes was stimulated by pro-inflammatory agents, including cytokines IL-1β/IFN-γ or the toll-like receptor 3 ligand polyinosinic:polycytidylic acid (poly I:C) [47].”
BackgroundInfluentialHoller, C. J., Taylor, G., Deng, Q., & Kukar, T. (2017) · eneuro · doi:10.1523/eneuro.0100-17.2017 · Cited by 136 · cited 5×
“When we consider that many of the reported studies on PGRN used different antibodies for measurements or cellular localization in tissue, it needs to be mentioned that detection of PGRN or granulin in complex tissue can have technical issues that significantly affect results [43].”
BackgroundInfluentialEgashira, Y., Suzuki, Y., Azuma, Y., Takagi, T., Mishiro, K., Sugitani, S., Tsuruma, K., Shimazawa, M., Yoshimura, S., Kashimata, M., et al. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-105 · Cited by 135 · cited 6×
“In the extracellular space, PGRN may be cleaved into granulins by different proteases such as neutrophil elastase [46], matrix metalloproteinase (MMP)-9, MMP-12 [47] and ADAMTS7 [48].”
BackgroundInfluentialThe endocytic pathway in microglia during health, aging and Alzheimer’s disease
Solé-Domènech, S., Cruz, D. L., Capetillo-Zarate, E., & Maxfield, F. R. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.07.002 · Cited by 133 · cited 1×
“Lysosomal function is also directly connected to microglial activation states and inflammation [142] with lysosomes being required to remove unwanted proteins, such as aggregated Aβ and tau, phagocytosed by microglia.”
BackgroundKrabbe, G., Minami, S. S., Etchegaray, J. I., Taneja, P., Djukic, B., Davalos, D., Le, D., Lo, I., Zhan, L., Reichert, M. C., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700477114 · Cited by 132
EphA2 is a functional receptor for the growth factor progranulin
Neill, T., Buraschi, S., Goyal, A., Sharpe, C., Natkanski, E., Schaefer, L., Morrione, A., & Iozzo, R. V. (2016) · Journal of Cell Biology · doi:10.1083/jcb.201603079 · Cited by 131
Translating the biology of aging into novel therapeutics for Alzheimer disease
Hara, Y., McKeehan, N., & Fillit, H. M. (2019) · Neurology · doi:10.1212/wnl.0000000000006745 · Cited by 122 · cited 1×
“However, there is urgent need for new therapeutic targets for AD and other neurodegenerative diseases; firstly, though greater understanding of the complex disease mechanisms involved is needed [4,5].”
BackgroundGenetic targeting of microglia
Wieghofer, P., Knobeloch, K.-P., & Prinz, M. (2015) · Glia · doi:10.1002/glia.22727 · Cited by 117 · cited 1×
“In particular, LysM-Cre constructs to induce knockout of microglia have identified technical concerns about the reliability, efficiency and selectivity of this method, therefore the validity of conclusions from these studies have to be critically examined [117,118].”
BackgroundProgranulin: A key player in autoimmune diseases
Jian, J., Li, G., Hettinghouse, A., & Liu, C. (2018) · Cytokine · doi:10.1016/j.cyto.2016.08.007 · Cited by 112
Chen, X., Chang, J., Deng, Q., Xu, J., Nguyen, T. A., Martens, L. H., Cenik, B., Taylor, G., Hudson, K. F., Chung, J., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.5336-12.2013 · Cited by 109 · cited 1×
“However, other studies have not replicated these findings [97,98]; this issue is still unresolved [99].”
BackgroundSuárez‐Calvet, M., Capell, A., Araque Caballero, M. Á., Morenas‐Rodríguez, E., Fellerer, K., Franzmeier, N., Kleinberger, G., Eren, E., Deming, Y., Piccio, L., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809712 · Cited by 109 · cited 3×
“Furthermore, in late-onset AD cases, higher CSF PGRN levels were associated with more advanced disease stages and cognitive impairment, and once pathology had commenced correlated with CSF levels of soluble triggering receptor expressed on myeloid cells 2 (TREM2) [76].”
BackgroundHoller, C. J., Taylor, G., McEachin, Z. T., Deng, Q., Watkins, W. J., Hudson, K., Easley, C. A., Hu, W. T., Hales, C. M., Rossoll, W., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0114-3 · Cited by 108 · cited 1×
“However, alternative mechanisms of regulation of PGRN were identified since cells and mice treated with trehalose, a mammalian Target of Rapamycin (mTOR)-independent activator of autophagy, had elevated levels of PGRN; an effect not dependent on TFEB activation [38].”
BackgroundProgranulin is a chemoattractant for microglia and stimulates their endocytic activity
Pickford, F., Marcus, J., Camargo, L. M., Xiao, Q., Graham, D., Mo, J.-R., Burkhardt, M., Kulkarni, V., Crispino, J., Hering, H., et al. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2010.11.002 · Cited by 107
The lysosomal protein cathepsin L is a progranulin protease
Lee, C. W., Stankowski, J. N., Chew, J., Cook, C. N., Lam, Y.-W., Almeida, S., Carlomagno, Y., Lau, K.-F., Prudencio, M., Gao, F.-B., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0196-6 · Cited by 107 · cited 1×
“Although PGRN can be processed in lysosomes into granulin molecules by enzymes such as MMP12, cathepsin D and cathepsin L [43,145], it is full-length PGRN that has essential roles for maintaining lysosomal function.”
BackgroundZheng, Y., Brady, O. A., Meng, P. S., Mao, Y., & Hu, F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021023 · Cited by 105 · cited 1×
“Of particular interest in relation to inflammation are the following molecules that can interact with PGRN; Toll-like receptor (TLR)-9 [103], sortilin [44,104], receptor tyrosine kinase receptor EphA2 [105] and prosaposin [106].”
BackgroundGötzl, J. K., Colombo, A.-V., Fellerer, K., Reifschneider, A., Werner, G., Tahirovic, S., Haass, C., & Capell, A. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0281-5 · Cited by 94 · cited 2×
“Gene expression profiling of Grn deletion mice at 6 months and 12 months demonstrated significant changes in expression of only 8 genes with the largest changes being for CD68, CD63 and LAMP1, all lysosomal membrane proteins [138].”
BackgroundAssociation Between Progranulin and Gaucher Disease
Jian, J., Zhao, S., Tian, Q.-Y., Liu, H., Zhao, Y., Chen, W.-C., Grunig, G., Torres, P. A., Wang, B. C., Zeng, B., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.08.004 · Cited by 93 · cited 1×
“Recently, PGRN deficiency has been associated with Gaucher disease, a lysosomal storage disease that affects many organs and results in significant neurological complications [18].”
BackgroundProsaposin is a regulator of progranulin levels and oligomerization
Nicholson, A. M., Finch, N. A., Almeida, M., Perkerson, R. B., van Blitterswijk, M., Wojtas, A., Cenik, B., Rotondo, S., Inskeep, V., Almasy, L., et al. (2016) · Nature Communications · doi:10.1038/ncomms11992 · Cited by 91 · cited 3×
“This oligomerization of PGRN being regulated by the PGRN-interacting protein PSAP [132].”
BackgroundPGRN protects against colitis progression in mice in an IL-10 and TNFR2 dependent manner
Wei, F., Zhang, Y., Jian, J., Mundra, J. J., Tian, Q., Lin, J., Lafaille, J. J., Tang, W., Zhao, W., Yu, X., et al. (2014) · Scientific Reports · doi:10.1038/srep07023 · Cited by 90
Mo, J., Li, J., Yang, Z., Liu, Z., & Feng, J. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.469 · Cited by 90
Jiao, J., Herl, L. D., Farese, R. V., & Gao, F.-B. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010551 · Cited by 89 · cited 1×
“Increased levels of miRNA 29b and miRNA 15/107 reduced protein levels of PGRN in different cell types [33,34].”
BackgroundProgranulin as a biomarker and potential therapeutic agent
Abella, V., Pino, J., Scotece, M., Conde, J., Lago, F., González-Gay, M. Á., Mera, A., Gómez, R., Mobasheri, A., & Gualillo, O. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.06.006 · Cited by 89
Progranulin expression in advanced human atherosclerotic plaque
Kojima, Y., Ono, K., Inoue, K., Takagi, Y., Kikuta, K., Nishimura, M., Yoshida, Y., Nakashima, Y., Matsumae, H., Furukawa, Y., et al. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.02.017 · Cited by 88
Rhost, S., Hughes, É., Harrison, H., Rafnsdóttir, S., Jacobsson, H., Gregersson, P., Magnusson, Y., Fitzpatrick, P., Andersson, D., Berger, K., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1060-5 · Cited by 88
Pereson, S., Wils, H., Kleinberger, G., McGowan, E., Vandewoestyne, M., Van Broeck, B., Joris, G., Cuijt, I., Deforce, D., Hutton, M., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2580 · Cited by 87
Gene expression study on peripheral blood identifies progranulin mutations
Coppola, G., Karydas, A., Rademakers, R., Wang, Q., Baker, M., Hutton, M., Miller, B. L., & Geschwind, D. H. (2008) · Annals of Neurology · doi:10.1002/ana.21397 · Cited by 87
Restoring neuronal progranulin reverses deficits in a mouse model of frontotemporal dementia
Arrant, A. E., Filiano, A. J., Unger, D. E., Young, A. H., & Roberson, E. D. (2017) · Brain · doi:10.1093/brain/awx060 · Cited by 87
Deletion of progranulin exacerbates atherosclerosis in ApoE knockout mice
Kawase, R., Ohama, T., Matsuyama, A., Matsuwaki, T., Okada, T., Yamashita, T., Yuasa-Kawase, M., Nakaoka, H., Nakatani, K., Inagaki, M., et al. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvt178 · Cited by 85 · cited 2×
“In mice fed a high fat diet to induce atherosclerosis, those with Grn deletion combined with apolipoprotein E (apoE) knockout had enhanced atherosclerotic lesions compared to apoE knockout mice with intact Grn genes [61].”
BackgroundCarecchio, M., Fenoglio, C., Riz, M. A. D., Guidi, I., Comi, C., Cortini, F., Venturelli, E., Restelli, I., Cantoni, C., Bresolin, N., et al. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.07.011 · Cited by 83 · cited 5×
“Furthermore, in late-onset AD cases, higher CSF PGRN levels were associated with more advanced disease stages and cognitive impairment, and once pathology had commenced correlated with CSF levels of soluble triggering receptor expressed on myeloid cells 2 (TREM2) [76].”
BackgroundInfluentialMicroglial Upregulation of Progranulin as a Marker of Motor Neuron Degeneration
Philips, T., De Muynck, L., Nguyen Thi Thu, H., Weynants, B., Vanacker, P., Dhondt, J., Sleegers, K., Schelhaas, H. J., Verbeek, M., Vandenberghe, R., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181fc9aea · Cited by 83 · cited 1×
“In a mouse model of motor neuron disease/amyotrophic lateral sclerosis (ALS) due to overexpression of mutant superoxide dismutase (SOD)-1, significantly increased levels of Grn mRNA and PGRN protein were detected in spinal cord samples after disease symptoms had started [113].”
BackgroundInitiative, F. T. A. D. N., Takahashi, H., Klein, Z. A., Bhagat, S. M., Kaufman, A. C., Kostylev, M. A., Ikezu, T., & Strittmatter, S. M. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1668-z · Cited by 83
Bhandari, V., Giaid, A., & Bateman, A. (1993) · Endocrinology · doi:10.1210/en.133.6.2682 · Cited by 78 · cited 1×
“Although expression in many different cell lines has been detected, Grn expression in tissue appeared more restricted [56].”
BackgroundScholtzova, H., Chianchiano, P., Pan, J., Sun, Y., Goñi, F., Mehta, P. D., & Wisniewski, T. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0101-2 · Cited by 77
Progranulin Gene Delivery Protects Dopaminergic Neurons in a Mouse Model of Parkinson’s Disease
Van Kampen, J. M., Baranowski, D., & Kay, D. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097032 · Cited by 76 · cited 5×
“This group used the same PGRN gene therapy vector to protect dopaminergic neurons in the substantia nigra of a toxin-induced Parkinson’s disease (PD) animal model [152].”
BackgroundMethodInfluentialStructure and chromosomal location of the human granulin gene
Bhandari, V., & Bateman, A. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)92349-3 · Cited by 75 · cited 1×
“The human GRN gene codes for a 593 amino acid glycoprotein (PGRN) of 75–80 kDa [39] consisting of highly-conserved 12-cysteine-rich granulin motifs that are tandemly repeated seven and half times [40].”
BackgroundThe Progranulin Cleavage Products, Granulins, Exacerbate TDP-43 Toxicity and Increase TDP-43 Levels
Salazar, D. A., Butler, V. J., Argouarch, A. R., Hsu, T.-Y., Mason, A., Nakamura, A., McCurdy, H., Cox, D., Ng, R., Pan, G., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.4808-14.2015 · Cited by 74 · cited 1×
“In comparison to PGRN, granulins can have a range of pro-inflammatory functions [42].”
BackgroundIncreased Serum GP88 (Progranulin) Concentrations in Rheumatoid Arthritis
Yamamoto, Y., Takemura, M., Serrero, G., Hayashi, J., Yue, B., Tsuboi, A., Kubo, H., Mitsuhashi, T., Mannami, K., Sato, M., et al. (2014) · Inflammation · doi:10.1007/s10753-014-9911-4 · Cited by 74 · cited 1×
“Increased levels of PGRN have been detected in serum of RA subjects compared to controls [101,102].”
BackgroundBrain progranulin expression in GRN-associated frontotemporal lobar degeneration
Chen-Plotkin, A. S., Xiao, J., Geser, F., Martinez-Lage, M., Grossman, M., Unger, T., Wood, E. M., Van Deerlin, V. M., Trojanowski, J. Q., & Lee, V. M.-Y. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0576-2 · Cited by 73
Progranulin expression is upregulated after spinal contusion in mice
Naphade, S. B., Kigerl, K. A., Jakeman, L. B., Kostyk, S. K., Popovich, P. G., & Kuret, J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0616-y · Cited by 72 · cited 1×
“In mice subjected to spinal cord contusion injury, a large increase in expression of PGRN was detected in activated microglia/macrophages around the sites of injury, while uninjured mice showed very low levels of spinal cord PGRN expression [64].”
BackgroundLiu, F., Zhang, W., Yang, F., Feng, T., Zhou, M., Yu, Y., Yu, X., Zhao, W., Yi, F., Tang, W., et al. (2016) · Scientific Reports · doi:10.1038/srep21260 · Cited by 72 · cited 1×
“Interleukin (IL)-6 directly induced PGRN levels in liver carcinoma cells [36]; the GRN gene promoter contains IL-6 response element sequences.”
BackgroundAlmeida, S., Zhou, L., & Gao, F.-B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026454 · Cited by 71 · cited 1×
“Many of the biological properties of PGRN are dependent on its accumulation in lysosomes, its secretion and endocytosis by neighboring cells and its interactions with other proteins [44,45].”
BackgroundThe Evolution of the Secreted Regulatory Protein Progranulin
Palfree, R. G. E., Bennett, H. P. J., & Bateman, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133749 · Cited by 70 · cited 1×
“The GRN/Grn gene is highly conserved across lower species including insects and fish [25].”
BackgroundFenoglio, C., Galimberti, D., Cortini, F., Kauwe, J. S. K., Cruchaga, C., Venturelli, E., Villa, C., Serpente, M., Scalabrini, D., Mayo, K., et al. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1170 · Cited by 68 · cited 2×
“Studies on the outcomes of complete loss of microglial PGRN on AD type pathology are needed [24], though the limited loss of microglial PGRN might more accurately represent the features of early AD [23].”
BackgroundProgranulin mutations in ubiquitin-positive frontotemporal dementia linked to chromosome 17q21
Cruts, M., Kumar-Singh, S., & Van Broeckhoven, C. (2006) · Current Alzheimer Research · doi:10.2174/156720506779025251 · Cited by 67
Progranulin polymorphism rs5848 is associated with increased risk of Alzheimer's disease
Sheng, J., Su, L., Xu, Z., & Chen, G. (2014) · Gene · doi:10.1016/j.gene.2014.03.041 · Cited by 65 · cited 2×
“gene has been associated with significant altered risk of developing AD [21,22].”
BackgroundToh, H., Cao, M., Daniels, E., & Bateman, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064989 · Cited by 62
The role of progranulin in arthritis
Wei, J., Hettinghouse, A., & Liu, C.-J. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13191 · Cited by 62
Beel, S., Herdewyn, S., Fazal, R., De Decker, M., Moisse, M., Robberecht, W., Van Den Bosch, L., & Van Damme, P. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0288-y · Cited by 61 · cited 3×
“It was shown that increased amounts of PGRN could reduce the levels of degenerative pathology and neuronal deposits of TDP-43 in TDP-43 mutant mice being used as a model for ALS [66].”
BackgroundAlzheimer’s Disease: Advances in Drug Development
Piton, M., Hirtz, C., Desmetz, C., Milhau, J., Lajoix, A. D., Bennys, K., Lehmann, S., & Gabelle, A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180145 · Cited by 60
Progranulin Reduction Is Associated With Increased Tau Phosphorylation in P301L Tau Transgenic Mice
Hosokawa, M., Arai, T., Masuda-Suzukake, M., Kondo, H., Matsuwaki, T., Nishihara, M., Hasegawa, M., & Akiyama, H. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000158 · Cited by 59
Progranulin expression in brain tissue and cerebrospinal fluid levels in multiple sclerosis
Vercellino, M., Grifoni, S., Romagnolo, A., Masera, S., Mattioda, A., Trebini, C., Chiavazza, C., Caligiana, L., Capello, E., Mancardi, G. L., et al. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511406164 · Cited by 58 · cited 1×
“There were increased PGRN CSF levels and microglial expression in tissue from multiple sclerosis cases with relapsing-remitting or progressive disease [83].”
BackgroundGalimberti, D., Fumagalli, G. G., Fenoglio, C., Cioffi, S. M. G., Arighi, A., Serpente, M., Borroni, B., Padovani, A., Tagliavini, F., Masellis, M., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.10.016 · Cited by 58 · cited 1×
“Others have suggested that serum/plasma PGRN levels can have disease diagnostic value for undiagnosed and presymptomatic FTLD [89].”
BackgroundAmado, D. A., Rieders, J. M., Diatta, F., Hernandez-Con, P., Singer, A., Mak, J. T., Zhang, J., Lancaster, E., Davidson, B. L., & Chen-Plotkin, A. S. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.013 · Cited by 58
Three TNFR-binding domains of PGRN act independently in inhibition of TNF-alpha binding and activity
Tian, Q., Zhao, Y., Mundra, J. J., Gonzalez-Gugel, E., Jian, J., Uddin, S. M. Z., & Liu, C. (2014) · Frontiers in bioscience · doi:10.2741/4274 · Cited by 56 · cited 1×
“Certain studies concluded that the central mechanism of inhibiting inflammation was the binding and antagonism by PGRN of the tumor necrosis factor receptor (TNFR)-1 and TNFR-2 [95,96], thus blocking the action of the proinflammatory cytokine tumor necrosis factor (TNF-α).”
BackgroundKocerha, J., Kouri, N., Baker, M., Finch, N., DeJesus-Hernandez, M., Gonzalez, J., Chidamparam, K., Josephs, K. A., Boeve, B. F., Graff-Radford, N. R., et al. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-527 · Cited by 55 · cited 1×
“These results were validated in frontal cortex for 9 of the 20 miRNAs, with additional measurements showing miRNAs miR-922, miR-516a-3p, miR-571, miR-548b-5p, and miR-548c-5p were also significantly dysregulated in cerebellar tissue samples of GRN mutation carriers [35].”
ResultMundra, J. J., Jian, J., Bhagat, P., & Liu, C.-J. (2016) · Scientific Reports · doi:10.1038/srep21115 · Cited by 55 · cited 1×
“It has been shown that PGRN can block the downstream activity of TNF-α by inhibiting the expression and release of CXCL9, CXCL10 or IL-10 [58,100].”
BackgroundLoss of exosomes in progranulin-associated frontotemporal dementia
Benussi, L., Ciani, M., Tonoli, E., Morbin, M., Palamara, L., Albani, D., Fusco, F., Forloni, G., Glionna, M., Baco, M., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.01.001 · Cited by 54 · cited 1×
“Significantly reduced numbers of exosomes were produced from SH-SY5Y cells following GRN silencing or from fibroblast cells derived from FTLD cases with PGRN mutations [52].”
BackgroundWalker, D. G., Tang, T. M., & Lue, L.-F. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.07.016 · Cited by 52 · cited 1×
“Although TLR-9 immunolocalization has not been demonstrated in human brains as its expression levels appear to be very low [135], it has been”
BackgroundSelf-citationUpdate on Frontotemporal Dementia
Arvanitakis, Z. (2010) · The Neurologist · doi:10.1097/nrl.0b013e3181b1d5c6 · Cited by 51 · cited 1×
“FTLD is a common cause of early onset dementia in people under 65 years of age [19].”
BackgroundTMEM106B expression is reduced in Alzheimer’s disease brains
Satoh, J.-I., Kino, Y., Kawana, N., Yamamoto, Y., Ishida, T., Saito, Y., & Arima, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt247 · Cited by 51 · cited 3×
“TMEM106B mRNA levels were significantly decreased in AD cases compared to controls, while Grn mRNA levels were increased [123].”
BackgroundInfluentialGRN Variant rs5848 Reduces Plasma and Brain Levels of Granulin in Alzheimer's Disease Patients
Kämäläinen, A., Viswanathan, J., Natunen, T., Helisalmi, S., Kauppinen, T., Pikkarainen, M., Pursiheimo, J.-P., Alafuzoff, I., Kivipelto, M., Haapasalo, A., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120946 · Cited by 50 · cited 5×
“The single nucleotide polymorphism (SNP) rs5848 T allele in the GRN gene has been associated with significant altered risk of developing AD [21,22].”
BackgroundInfluentialAssociation of progranulin polymorphism rs5848 with neurodegenerative diseases: a meta-analysis
Chen, Y., Li, S., Su, L., Sheng, J., Lv, W., Chen, G., & Xu, Z. (2015) · Journal of Neurology · doi:10.1007/s00415-014-7630-2 · Cited by 50
Activity-dependent secretion of progranulin from synapses
Petoukhov, E., Fernando, S., Mills, F., Shivji, F., Hunter, D., Krieger, C., Silverman, M. A., & Bamji, S. X. (2013) · Journal of Cell Science · doi:10.1242/jcs.132076 · Cited by 50 · cited 1×
“This was diminished with inhibition of neuronal excitation by blocking voltage-gated calcium channels [50].”
BackgroundLu, R., & Serrero, G. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0253 · Cited by 49
Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias
Morenas-Rodríguez, E., Cervera-Carles, L., Vilaplana, E., Alcolea, D., Carmona-Iragui, M., Dols-Icardo, O., Ribosa-Nogué, R., Muñoz-Llahuna, L., Sala, I., Belén Sánchez-Saudinós, M., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150746 · Cited by 49 · cited 1×
“Earlier studies showed little utility for PGRN levels as a useful diagnostic biomarker for AD [22,77].”
BackgroundZhou, X., Sun, L., Brady, O. A., Murphy, K. A., & Hu, F. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0412-1 · Cited by 49
Recent Advances in Multi-target Anti-Alzheimer Disease Compounds (2013 Up to the Present)
Wang, N., Qiu, P., Cui, W., Yan, X., Zhang, B., & He, S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867326666181203124102 · Cited by 49 · cited 1×
“However, there is urgent need for new therapeutic targets for AD and other neurodegenerative diseases; firstly, though greater understanding of the complex disease mechanisms involved is needed [4,5].”
BackgroundDysregulation of the mitogen granulin in human cancer through the miR-15/107 microRNA gene group
Wang, W.-X., Kyprianou, N., Wang, X., & Nelson, P. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1684 · Cited by 48 · cited 2×
“Increased levels of miRNA 29b and miRNA 15/107 reduced protein levels of PGRN in different cell types [33,34].”
BackgroundNew discovery rarely runs smooth: an update on progranulin/TNFR interactions
Wang, B. C., Liu, H. W., Talwar, A. A., & Jian, J. (2015) · Protein & Cell · doi:10.1007/s13238-015-0213-x · Cited by 48 · cited 1×
“However, other studies have not replicated these findings [97,98]; this issue is still unresolved [99].”
BackgroundRegulation of progranulin expression in myeloid cells
Ong, C., He, Z., Kriazhev, L., Shan, X., Palfree, R. G. E., & Bateman, A. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00616.2005 · Cited by 47 · cited 2×
“GRN mRNA expression and PGRN protein levels in a number of myeloid cell lines were most strongly induced by all-trans retinoic acid (vitamin A) and, to lesser extents, by the protein kinase C (PKC) activator phorbol myristate acetate (PMA) and dimethyl sulfoxide (DMSO) [27].”
BackgroundVan Kampen, J. M., & Kay, D. G. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182896 · Cited by 47 · cited 3×
“Animals sacrificed 4 months after gene administration had significantly lower plaque loads in the hippocampus (CA1 and dentate gyrus), entorhinal cortex and frontal cortex, and significantly higher levels of the Aβ-degrading enzyme neprilysin [151].”
BackgroundMethodAge-Dependent Changes in Progranulin Expression in the Mouse Brain
Matsuwaki, T., Asakura, R., Suzuki, M., Yamanouchi, K., & Nishihara, M. (2010) · Journal of Reproduction and Development · doi:10.1262/jrd.10-116s · Cited by 46 · cited 1×
“In this study, an overall decrease in PGRN expression with age was observed [63].”
BackgroundZhou, X., Sullivan, P. M., Sun, L., & Hu, F. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14110 · Cited by 44 · cited 1×
“PSAP and PGRN have physical interactions through GRN linker sequences and facilitate trafficking of each other to lysosomes through a sortilin-independent pathway [136,137].”
BackgroundUngurs, M. J., Sinden, N., & Stockley, R. A. (2013) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00221.2013 · Cited by 42 · cited 1×
“In the extracellular space, PGRN may be cleaved into granulins by different proteases such as neutrophil elastase [46], matrix metalloproteinase (MMP)-9, MMP-12 [47] and ADAMTS7 [48].”
BackgroundLang, I., Füllsack, S., & Wajant, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00793 · Cited by 42 · cited 1×
“However, other studies have not replicated these findings [97,98]; this issue is still unresolved [99].”
BackgroundStructural and functional analysis of a promoter of the human granulin/epithelin gene
BHANDARI, V., DANIEL, R. L., Lim, S. P., & Bateman, A. (1996) · Biochemical Journal · doi:10.1042/bj3190441 · Cited by 39 · cited 1×
“The regulation of GRN gene expression is complex as the gene promoter contains binding sites for a number of different transcription regulators, many of which are activated in inflammation [26].”
BackgroundInduction of granulin precursor gene expression by estrogen treatment in neonatal rat hypothalamus
Suzuki, M., Yonezawa, T., Fujioka, H., Matuamuro, M., & Nishihara, M. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01699-2 · Cited by 39 · cited 1×
“Other studies showed increased PGRN levels in response to estradiol in breast cancer cells [28] and to estrogen in hypothalamus [29].”
BackgroundKörtvélyessy, P., Gukasjan, A., Sweeney‐Reed, C. M., Heinze, H., Thurner, L., & Bittner, D. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150069 · Cited by 37 · cited 1×
“However, a more recent study showed PGRN CSF levels correlated significantly with frontal lobe memory functions in AD cases, while Aβ42 CSF levels correlated with temporal lobe memory functions [86].”
BackgroundSerum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease
Wilke, C., Gillardon, F., Deuschle, C., Dubois, E., A. Hobert, M., Müller vom Hagen, J., Krüger, S., Biskup, S., Blauwendraat, C., Hruscha, M., et al. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160314151247 · Cited by 37
Petkau, T. L., Kosior, N., de Asis, K., Connolly, C., & Leavitt, B. R. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1000-9 · Cited by 35 · cited 3×
“Induced deficiency of microglial PGRN employed mice expressing Cre recombinase knocked in to the Lys2 locus (LysMCre) crossed with Grn flox/flox mice [114], while induced deficiency of neuronal PGRN employed Cre recombinase knocked in on the CaMKII locus (CaMKII-Cre) crossed with Grn flox/flox mice [115].”
BackgroundMethodResultBiochemistry and Physiological Functions of ADAMTS7 Metalloprotease
Hanby, H. A., & Zheng, X. L. (2013) · Advances in Biochemistry · doi:10.11648/j.ab.20130103.11 · Cited by 34 · cited 1×
“In the extracellular space, PGRN may be cleaved into granulins by different proteases such as neutrophil elastase [46], matrix metalloproteinase (MMP)-9, MMP-12 [47] and ADAMTS7 [48].”
BackgroundSikora, J., HARZER, K., & Elleder, M. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0148-7 · Cited by 34
Hypoxia induces up-regulation of progranulin in neuroblastoma cell lines
Piscopo, P., Rivabene, R., Adduci, A., Mallozzi, C., Malvezzi‐Campeggi, L., Crestini, A., & Confaloni, A. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.09.008 · Cited by 33 · cited 1×
“Another complex mechanism involved hypoxia, which induced PGRN mRNA and protein in human neuroblastoma cell lines [31] as a result of activation of the mitogen-activated protein kinases (MAPK)/extracellular signal-regulated kinase (MEK) signaling cascade [31].”
BackgroundAntonell, A., Gil, S., Sánchez-Valle, R., Balasa, M., Bosch, B., Prat, M. C., Chiollaz, A.-C., Fernández, M., Yagüe, J., Molinuevo, J. L., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-112120 · Cited by 31 · cited 1×
“Serum PGRN levels were not different between control and AD cases and were reduced in subjects with GRN mutations [87].”
BackgroundCatacLysMic specificity when targeting myeloid cells?
Blank, T., & Prinz, M. (2016) · European Journal of Immunology · doi:10.1002/eji.201646437 · Cited by 31
Secreted Progranulin Is a Homodimer and Is Not a Component of High Density Lipoproteins (HDL)
Nguyen, A. D., Nguyen, T. A., Cenik, B., Yu, G., Herz, J., Walther, T. C., Davidson, W. S., & Farese, R. V. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.441949 · Cited by 30 · cited 1×
“This homodimer was resistant to the activity of reducing agents; therefore did not contain disulfide bonds [51].”
BackgroundProgranulin promotes activation of microglia/macrophage after pilocarpine-induced status epilepticus
Zhu, S., Tai, C., Petkau, T. L., Zhang, S., Liao, C., Dong, Z., Wen, W., Chang, Q., Wang, Y. T., MacVicar, B. A., et al. (2013) · Brain Research · doi:10.1016/j.brainres.2013.07.023 · Cited by 30 · cited 1×
“In animals treated with pilocarpine to induce status epilepticus, there was increased expression of PGRN in neurons and microglia [60].”
BackgroundReduced serum progranulin level might be associated with Parkinson's disease risk
Mateo, I., González‐Aramburu, I., Pozueta, A., Vázquez‐Higuera, J. L., Rodríguez‐Rodríguez, E., Sánchez‐Juan, P., Calero, M., Dobato, J. L., Infante, J., Berciano, J., et al. (2013) · European Journal of Neurology · doi:10.1111/ene.12090 · Cited by 30
Buraschi, S., Xu, S., Stefanello, M., Moskalev, I., Morcavallo, A., Genua, M., Tanimoto, R., Birbe, R., Peiper, S. C., Gomella, L. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9556 · Cited by 30
Chen, J., Saito, S., Kobayashi, N., Sato, K., Terashita, T., Shimokawa, T., Mominoki, K., Miyawaki, K., Sano, A., & Matsuda, S. (2007) · Neuroscience Research · doi:10.1016/j.neures.2007.09.010 · Cited by 28 · cited 2×
“Although it has not been shown that human brain microglia express PSAP in vivo, expression of PSAP mRNA in microglia in rat facial nerve after injury has been demonstrated [106].”
BackgroundWilke, C., Gillardon, F., Deuschle, C., Hobert, M. A., Jansen, I. E., Metzger, F. G., Heutink, P., Gasser, T., Maetzler, W., Blauwendraat, C., et al. (2016) · Neurodegenerative Diseases · doi:10.1159/000448896 · Cited by 28 · cited 1×
“CSF PGRN levels, not serum PGRN levels, were reduced in non-GRN mutation FTD cases [90].”
BackgroundArrant, A. E., Filiano, A. J., Patel, A. R., Hoffmann, M. Q., Boyle, N. R., Kashyap, S. N., Onyilo, V. C., Young, A. H., & Roberson, E. D. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.11.011 · Cited by 28 · cited 4×
“Induced deficiency of microglial PGRN employed mice expressing Cre recombinase knocked in to the Lys2 locus (LysMCre) crossed with Grn flox/flox mice [114], while induced deficiency of neuronal PGRN employed Cre recombinase knocked in on the CaMKII locus (CaMKII-Cre) crossed with Grn flox/flox mice [115].”
BackgroundMethodInfluentialCirculating progranulin as a biomarker for neurodegenerative diseases.
Ghidoni, R., Paterlini, A., & Benussi, L. (2012) · Europe PMC (PubMed Central) · Cited by 27
Progranulin aggravates pulmonary immunopathology during influenza virus infection
Luo, Q., Yan, X., Tu, H., Yin, Y., & Cao, J. (2018) · Thorax · doi:10.1136/thoraxjnl-2018-211916 · Cited by 27
Zhou, F., Jiang, J., Griffith, C. M., Patrylo, P. R., Cai, H., Chu, Y., & Yan, X. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0370-2 · Cited by 26 · cited 1×
“Immunohistochemistry for sortilin was confirmed in an AD mouse model, though extracellular sortilin bound to plaques was a feature only observed in human AD brains [133].”
BackgroundDíaz-Cueto, L., Arechavaleta-Velasco, F., Diaz-Arizaga, A., Domínguez-López, P., & Robles‐Flores, M. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e318253499c · Cited by 24 · cited 1×
“Inhibiting PKC and phosphatidylinositol 3-kinase (PI3K) diminished PGRN protein amounts in ovarian cancer cell lines, while inhibition of protein kinase A, p38, extracellular signal-regulated kinase and Akt did not affect protein levels [30].”
BackgroundEffects of hypoxia on progranulin expression in HT22 mouse hippocampal cells
Luo, L., Lü, L., Lu, Y., Zhang, L., Li, B., Guo, K., Chen, L., Wang, Y., Shao, Y., & XU, J. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2016 · Cited by 23 · cited 1×
“Similar findings were demonstrated in the mouse HT-22 neuronal cell line using sodium bisulfite to induce hypoxia [32].”
ResultGliebus, G., Rosso, A., & Lippa, C. F. (2009) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317509346209 · Cited by 22
Serum progranulin levels in relation to insulin resistance in childhood obesity
Alissa, E. M., Sutaih, R. H., Kamfar, H. Z., Al-Agha, A. E., & Marzouki, Z. M. (2017) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2017-0321 · Cited by 21
Progranulin haploinsufficiency reduces amyloid beta deposition in Alzheimer’s disease model mice
Hosokawa, M., Tanaka, Y., Arai, T., Kondo, H., Akiyama, H., & Hasegawa, M. (2017) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.17-0060 · Cited by 20
Daxer, J., Herttrich, T., Zhao, Y. Y., Vogel, M., Hiemisch, A., Scheuermann, K., Körner, A., Kratzsch, J., Kieß, W., & Quante, M. (2016) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2016-0378 · Cited by 19
Johnson, J., Yeter, K. C., Rajbhandary, R., Neal, R. A., Tian, Q., Jian, J., Fadle, N., Thurner, L., Liu, C.-J., & Stohl, W. (2016) · Clinical Rheumatology · doi:10.1007/s10067-016-3467-7 · Cited by 16 · cited 1×
“Increased levels of PGRN have been detected in serum of RA subjects compared to controls [101,102].”
BackgroundAssociation between progranulin serum levels and dietary intake
Nicoletto, B. B., Sarmento, R. A., Pedrollo, E. F., Krolikowski, T. C., & Canani, L. H. S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202149 · Cited by 16
Kimura, A., Takemura, M., Serrero, G., Yoshikura, N., Hayashi, Y., Saito, K., & Inuzuka, T. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2742-z · Cited by 14
Suh, H.-S., Gelman, B. B., & Lee, S. C. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9495-z · Cited by 13
Prognostic Value of Progranulin in Patients with Colorectal Cancer Treated with Curative Resection
On Behalf of the KBSMC Colorectal Cancer Team, Koo, D., Do, I., Oh, S., Lee, Y., Kim, K., Sohn, J. H., Park, S., Yang, H., Jung, Y. S., et al. (2018) · Pathology & Oncology Research · doi:10.1007/s12253-018-0520-7 · Cited by 9
Chen, X., Liu, J., Zhu, M., Hu, B., Bai, F.-X., Jin, W., Zhou, J., Chen, C., Song, Y., & Pan, J. (2018) · The Clinical Respiratory Journal · doi:10.1111/crj.12952 · Cited by 7
Wagner, H. (2011) · European Journal of Immunology · doi:10.1002/eji.201142056 · Cited by 6
Cited by
New insights into the genetic etiology of Alzheimer’s disease and related dementias
Bellenguez, C., Küçükali, F., Jansen, I. E., Kleineidam, L., Moreno-Grau, S., Amin, N., Naj, A. C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01024-z · Cited by 2,498
Advancing cell therapy for neurodegenerative diseases
Temple, S. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.03.017 · Cited by 198
Microglial Phagocytosis: A Disease-Associated Process Emerging from Alzheimer’s Disease Genetics
Podleśny-Drabiniok, A., Marcora, E., & Goate, A. M. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.10.002 · Cited by 211
Cell type-specific inference of differential expression in spatial transcriptomics
Cable, D. M., Murray, E., Shanmugam, V., Zhang, S., Zou, L. S., Diao, M., Chen, H., Macosko, E. Z., Irizarry, R. A., & Chen, F. (2022) · Nature Methods · doi:10.1038/s41592-022-01575-3 · Cited by 164
“…anti-inflammatory gene Grn was upregulated in microglia near plaque (log 2 fold-change 0.79, P = 6 × 10 − 4 ), consistent with previous knowledge 40 . progenitors create radial projections out from the hypothalamic midline, which are used as scaffolds for the migration of differentiating…”
BackgroundResultInfluentialCano, A., Turowski, P., Ettcheto, M., Duskey, J. T., Tosi, G., Sánchez-López, E., García, M. L., Camins, A., Souto, E. B., Ruiz, A., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00864-x · Cited by 122
“Progranulin, a glycoprotein mainly secreted by activated microglia, is involved in the modulation of neuroinflammation [73].”
Background
Metadata
- Authors
- Mendsaikhan, A., Tooyama, I., & Walker, D. G.
- Affiliations
- Shiga University of Medical Science (JP)
- Corresponding author
- Mendsaikhan, Anarmaa
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2019-03-11
- Volume
- 8
- Issue
- 3
- Pages
- 230
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC6468562
- OpenAlex
- W2920995467
- Cited by
- 72
- References
- 159
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 14 · 2023: 9 · 2022: 13 · 2021: 12 · 2020: 6 · 2019: 3
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science (26290022)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- progranulin, microglia, Alzheimer's disease, neurodegenerative diseases, frontotemporal lobar degeneration, neuronal ceroid lipofuscinosis, lysosomal dysfunction, neuroinflammation, anti-inflammatory activity, neurotrophic factors
- MeSH terms
- Progranulins, Alzheimer Disease, Animals, Disease Models, Animal, Humans, Lysosomes, Microglia, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.